IN2014DN06101A - - Google Patents
Download PDFInfo
- Publication number
- IN2014DN06101A IN2014DN06101A IN6101DEN2014A IN2014DN06101A IN 2014DN06101 A IN2014DN06101 A IN 2014DN06101A IN 6101DEN2014 A IN6101DEN2014 A IN 6101DEN2014A IN 2014DN06101 A IN2014DN06101 A IN 2014DN06101A
- Authority
- IN
- India
- Prior art keywords
- thieno
- prevention
- formula
- pharmaceutically acceptable
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Ophthalmology & Optometry (AREA)
- Physical Education & Sports Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20110146818 | 2011-12-30 | ||
| PCT/KR2012/011571 WO2013100632A1 (fr) | 2011-12-30 | 2012-12-27 | Dérivés thiéno[3,2-d]pyrimidines ayant une activité inhibitrice pour des protéines kinases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014DN06101A true IN2014DN06101A (fr) | 2015-08-14 |
Family
ID=48697978
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN6101DEN2014 IN2014DN06101A (fr) | 2011-12-30 | 2012-12-27 |
Country Status (33)
| Country | Link |
|---|---|
| US (2) | USRE47451E1 (fr) |
| EP (2) | EP3617213A1 (fr) |
| JP (1) | JP5797345B2 (fr) |
| KR (1) | KR101490761B1 (fr) |
| CN (1) | CN104039798B (fr) |
| AR (1) | AR089489A1 (fr) |
| AU (1) | AU2012363558C1 (fr) |
| BR (2) | BR112014015720B1 (fr) |
| CA (1) | CA2859668C (fr) |
| CL (1) | CL2014001729A1 (fr) |
| CO (1) | CO7010840A2 (fr) |
| DK (1) | DK2797927T3 (fr) |
| ES (1) | ES2751608T3 (fr) |
| HK (1) | HK1200833A1 (fr) |
| HR (1) | HRP20191840T8 (fr) |
| HU (1) | HUE045957T2 (fr) |
| IL (2) | IL233441B (fr) |
| IN (1) | IN2014DN06101A (fr) |
| LT (1) | LT2797927T (fr) |
| MX (2) | MX363659B (fr) |
| MY (1) | MY170988A (fr) |
| PE (1) | PE20141404A1 (fr) |
| PH (1) | PH12014501504A1 (fr) |
| PL (1) | PL2797927T3 (fr) |
| PT (1) | PT2797927T (fr) |
| RS (1) | RS59420B1 (fr) |
| RU (2) | RU2625799C2 (fr) |
| SG (2) | SG11201402765TA (fr) |
| SI (1) | SI2797927T1 (fr) |
| TW (1) | TWI462927B (fr) |
| UA (1) | UA109614C2 (fr) |
| WO (1) | WO2013100632A1 (fr) |
| ZA (1) | ZA201405583B (fr) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102132405B1 (ko) | 2010-05-20 | 2020-07-09 | 어레이 바이오파마 인크. | Trk 키나제 저해제로서의 매크로시클릭 화합물 |
| TWI713455B (zh) | 2014-06-25 | 2020-12-21 | 美商伊凡克特治療公司 | ＭｎＫ抑制劑及其相關方法 |
| SI3207023T1 (sl) | 2014-10-14 | 2020-07-31 | Syngenta Participations Ag | Postopek za pripravo 1-(3,5-diklorofenil)-2,2,2-trifluoroetanona in njegovih derivatov |
| LT3322706T (lt) | 2015-07-16 | 2021-03-10 | Array Biopharma, Inc. | Pakeistieji pirazolo[1,5-a]piridino junginiai, kaip ret kinazės inhibitoriai |
| US10112955B2 (en) | 2015-10-29 | 2018-10-30 | Effector Therapeutics, Inc. | Isoindoline, azaisoindoline, dihydroindenone and dihydroazaindenone inhibitors of Mnk1 and Mnk2 |
| JP6888006B2 (ja) | 2015-10-29 | 2021-06-16 | イーフェクター セラピューティクス， インコーポレイテッド | Ｍｎｋ１およびｍｎｋ２を阻害するピロロ−、ピラゾロ−、イミダゾ−ピリミジンおよびピリジン化合物 |
| US10000487B2 (en) | 2015-11-20 | 2018-06-19 | Effector Therapeutics, Inc. | Heterocyclic compounds that inhibit the kinase activity of Mnk useful for treating various cancers |
| WO2017114275A1 (fr) * | 2015-12-31 | 2017-07-06 | 成都先导药物开发有限公司 | Composé pour l'inhibition de la rock, son procédé de préparation et son utilisation |
| WO2017137334A1 (fr) * | 2016-02-08 | 2017-08-17 | F. Hoffmann-La Roche Ag | Spiroindolinones utilisés en tant qu'inhibiteurs de ddr1 |
| AU2017249229A1 (en) | 2016-04-15 | 2018-10-04 | Genentech, Inc. | Diagnostic and therapeutic methods for cancer |
| CN106153920B (zh) * | 2016-07-25 | 2018-04-27 | 四川大学华西医院 | 一种肺癌筛查试剂盒 |
| JOP20190077A1 (ar) | 2016-10-10 | 2019-04-09 | Array Biopharma Inc | مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret |
| TWI704148B (zh) | 2016-10-10 | 2020-09-11 | 美商亞雷生物製藥股份有限公司 | 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物 |
| PT3562821T (pt) * | 2016-12-28 | 2021-03-03 | Minoryx Therapeutics S L | Compostos de isoquinolina, métodos para a sua preparação e utilizações terapêuticas dos mesmos em condições associadas à alteração da atividade da beta-galactosidade |
| CA3049136C (fr) | 2017-01-18 | 2022-06-14 | Array Biopharma Inc. | Composes de pyrazolo[1,5-a]pyrazine substitues utilises en tant qu'inhibiteurs de la kinase ret |
| WO2018136663A1 (fr) | 2017-01-18 | 2018-07-26 | Array Biopharma, Inc. | Inhibiteurs de ret |
| JP2020507588A (ja) | 2017-02-14 | 2020-03-12 | イーフェクター セラピューティクス， インコーポレイテッド | ピぺリジン置換ＭｎＫ阻害剤およびそれに関連する方法 |
| JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
| AU2018308038B2 (en) | 2017-07-28 | 2022-02-03 | Yuhan Corporation | Improved process for preparing aminopyrimidine derivatives |
| AU2018329925A1 (en) | 2017-09-08 | 2020-03-05 | F. Hoffmann-La Roche Ag | Diagnostic and therapeutic methods for cancer |
| TW202410896A (zh) | 2017-10-10 | 2024-03-16 | 美商絡速藥業公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物 |
| TWI791053B (zh) | 2017-10-10 | 2023-02-01 | 美商亞雷生物製藥股份有限公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物 |
| EP3717492B1 (fr) * | 2017-11-30 | 2023-05-24 | Hanmi Pharm. Co., Ltd. | Composé de thiéno[3,2-d]pyrimidine ayant une activité inhibitrice pour des protéines kinases |
| ES2971644T3 (es) * | 2017-11-30 | 2024-06-06 | Hanmi Pharmaceutical Co Ltd | Sales de 4-amino-N-(1-((3-cloro-2-fluorofenil)amino)-6-metilisoquinolin-5-il)tieno[3,2-d]pirimidin-7-carboxamida y formas cristalinas de las mismas |
| US11524963B2 (en) | 2018-01-18 | 2022-12-13 | Array Biopharma Inc. | Substituted pyrazolo[3,4-d]pyrimidines as RET kinase inhibitors |
| JP6997876B2 (ja) | 2018-01-18 | 2022-02-04 | アレイ バイオファーマ インコーポレイテッド | Ｒｅｔキナーゼ阻害剤としての置換ピラゾリル［４，３－ｃ］ピリジン化合物 |
| JP7060694B2 (ja) | 2018-01-18 | 2022-04-26 | アレイ バイオファーマ インコーポレイテッド | Ｒｅｔキナーゼ阻害剤としての置換ピロロ［２，３－ｄ］ピリミジン化合物 |
| EP3752200A1 (fr) | 2018-02-13 | 2020-12-23 | Vib Vzw | Ciblage d'une maladie résiduelle minimale dans le cancer avec des antagonistes de rxr |
| EP3762379A1 (fr) | 2018-03-07 | 2021-01-13 | Bayer Aktiengesellschaft | Identification et utilisation d'inhibiteurs d'erk5 |
| US11964988B2 (en) | 2018-09-10 | 2024-04-23 | Array Biopharma Inc. | Fused heterocyclic compounds as RET kinase inhibitors |
| JP2022505846A (ja) | 2018-10-24 | 2022-01-14 | イーフェクター セラピューティクス， インコーポレイテッド | Ｍｎｋ阻害剤の結晶形態 |
| US20220040324A1 (en) | 2018-12-21 | 2022-02-10 | Daiichi Sankyo Company, Limited | Combination of antibody-drug conjugate and kinase inhibitor |
| CN110183464B (zh) * | 2019-05-31 | 2021-08-31 | 淮阴工学院 | 一种抗癌化合物艾斯替尼及其合成方法和应用 |
| KR20230031839A (ko) | 2020-05-26 | 2023-03-07 | 한미약품 주식회사 | 암 치료에 사용하기 위한 벨바라페닙 |
| US11351149B2 (en) | 2020-09-03 | 2022-06-07 | Pfizer Inc. | Nitrile-containing antiviral compounds |
| JP2023547306A (ja) | 2020-10-27 | 2023-11-10 | シチュアン ケルン－バイオテック バイオファーマシューティカル カンパニー リミテッド | アリールアミド化合物、それを含む医薬組成物、その製造方法及びそれらの使用 |
| US20240173329A1 (en) | 2021-03-09 | 2024-05-30 | Genentech, Inc. | Belvarafenib for use in treatment of brain cancers |
| JP2024514112A (ja) | 2021-04-06 | 2024-03-28 | ジェネンテック， インコーポレイテッド | ベルバラフェニブおよびコビメチニブを用いた併用療法、またはベルバラフェニブ、コビメチニブおよびアテゾリズマブを用いた併用療法 |
| WO2022216898A1 (fr) | 2021-04-09 | 2022-10-13 | Genentech, Inc. | Polythérapie comprenant un inhibiteur de raf et un inhibiteur de l'axe pd-1 |
| AU2022303488A1 (en) | 2021-06-30 | 2024-01-04 | F. Hoffmann-La Roche Ag | Synthesis of a bis-mesylate salt of 4-amino-n-(1 -((3-chloro-2- fluorophenyl)amino)-6-methylisoquinolin-5-yl)thieno[3,2- d]pyrimidine-7-carboxamide and intermediates thereto |
| CN114213430B (zh) * | 2021-12-28 | 2022-12-02 | 深圳湾实验室 | 4-氨基噻吩[3,2-d]嘧啶-7-羧酸的制备方法、蛋白激酶抑制剂中间体 |
| CN114524826A (zh) * | 2022-02-18 | 2022-05-24 | 郑州猫眼农业科技有限公司 | 7-溴-4-氯噻吩并[3,2-d]嘧啶的制备工艺 |
| TW202342766A (zh) | 2022-03-02 | 2023-11-01 | 瑞士商諾華公司 | 用於癌症治療之精準療法 |
| WO2024033381A1 (fr) | 2022-08-10 | 2024-02-15 | Vib Vzw | Inhibition de tcf4/itf2 dans le traitement du cancer |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0402518D0 (en) * | 2004-02-05 | 2004-03-10 | Astrazeneca Ab | Therapeutic agents |
| RU2528046C2 (ru) * | 2004-06-24 | 2014-09-10 | Вертекс Фармасьютикалз Инкорпорейтед | Модуляторы транспортеров атф-связывающей кассеты |
| GB0512324D0 (en) | 2005-06-16 | 2005-07-27 | Novartis Ag | Organic compounds |
| MY146795A (en) | 2005-06-09 | 2012-09-28 | Novartis Ag | Process for the synthesis of organic compounds |
| US7989461B2 (en) | 2005-12-23 | 2011-08-02 | Amgen Inc. | Substituted quinazolinamine compounds for the treatment of cancer |
| AU2007227602A1 (en) * | 2006-03-16 | 2007-09-27 | Novartis Ag | Heterocyclic organic compounds for the treatment of in particular melanoma |
| EP2004656B1 (fr) | 2006-04-07 | 2013-07-10 | Boehringer Ingelheim International GmbH | Thiénopyrimidines ayant une activité inhibitrice mnk1/mnk2 utilisées dans des compositions pharmaceutiques |
| WO2008044688A1 (fr) * | 2006-10-11 | 2008-04-17 | Daiichi Sankyo Company, Limited | Dérivé de l'urée |
| UA103478C2 (ru) | 2008-05-23 | 2013-10-25 | Новартіс Аг | Производные хинолинов и хиноксалинов как ингибиторы протеинтирозинкиназы |
| JP2012511021A (ja) * | 2008-12-05 | 2012-05-17 | アークル インコーポレイテッド | Ｒａｆの阻害剤およびその使用 |
| EP2403857B1 (fr) * | 2009-03-05 | 2013-12-04 | Takeda Pharmaceutical Company Limited | Thienopyrimidines comme inhibiteurs de la kinase cdc7 |
| DE102009035754A1 (de) | 2009-07-24 | 2011-01-27 | Hartmetall-Werkzeugfabrik Paul Horn Gmbh | Schneideinsatz für ein Schneidwerkzeug zur spanenden Bearbeitung, insbesondere zum Hochvorschubfräsen |
| CN102712646A (zh) * | 2009-08-28 | 2012-10-03 | 阵列生物制药公司 | Raf抑制剂化合物及其使用方法 |
| KR101147550B1 (ko) * | 2009-10-22 | 2012-05-17 | 한국과학기술연구원 | 단백질 키나아제 저해활성을 가지는 2,7-치환된 티에노［3,2-ｄ］피리미딘 화합물 |
| KR101094446B1 (ko) * | 2009-11-19 | 2011-12-15 | 한국과학기술연구원 | 단백질 키나아제 저해활성을 가지는 2,4,7-치환된 티에노［3,2-ｄ］피리미딘 화합물 |
| KR101483215B1 (ko) | 2010-01-29 | 2015-01-16 | 한미약품 주식회사 | 단백질 키나아제 저해활성을 갖는 비시클릭 헤테로아릴 유도체 |
| ES2636262T3 (es) * | 2010-01-29 | 2017-10-05 | Hanmi Science Co., Ltd. | Derivados de tieno[3,2-d]pirimidina que tienen actividad inhibidora en las proteínas cinasas |
| CA2802641C (fr) * | 2010-07-13 | 2019-03-12 | Nidhi Arora | Derives pyrazolo [1,5a] pyrimidine et thieno [3,2b] pyrimidine en tant que modulateurs de irak4 |
-
2012
- 2012-12-27 PE PE2014001048A patent/PE20141404A1/es active IP Right Grant
- 2012-12-27 EP EP19198802.1A patent/EP3617213A1/fr active Pending
- 2012-12-27 RU RU2014131390A patent/RU2625799C2/ru active
- 2012-12-27 MY MYPI2014701742A patent/MY170988A/en unknown
- 2012-12-27 IN IN6101DEN2014 patent/IN2014DN06101A/en unknown
- 2012-12-27 DK DK12861811T patent/DK2797927T3/da active
- 2012-12-27 US US15/783,240 patent/USRE47451E1/en active Active
- 2012-12-27 EP EP12861811.3A patent/EP2797927B1/fr active Active
- 2012-12-27 CN CN201280064739.8A patent/CN104039798B/zh active Active
- 2012-12-27 BR BR112014015720-0A patent/BR112014015720B1/pt active IP Right Grant
- 2012-12-27 PL PL12861811T patent/PL2797927T3/pl unknown
- 2012-12-27 US US14/363,857 patent/US9156852B2/en not_active Ceased
- 2012-12-27 RS RSP20191305 patent/RS59420B1/sr unknown
- 2012-12-27 WO PCT/KR2012/011571 patent/WO2013100632A1/fr active Application Filing
- 2012-12-27 BR BR122019019582-0A patent/BR122019019582B1/pt active IP Right Grant
- 2012-12-27 UA UAA201408629A patent/UA109614C2/ru unknown
- 2012-12-27 CA CA2859668A patent/CA2859668C/fr active Active
- 2012-12-27 MX MX2014007230A patent/MX363659B/es unknown
- 2012-12-27 SG SG11201402765TA patent/SG11201402765TA/en unknown
- 2012-12-27 AR ARP120105010A patent/AR089489A1/es active IP Right Grant
- 2012-12-27 SI SI201231684T patent/SI2797927T1/sl unknown
- 2012-12-27 HU HUE12861811A patent/HUE045957T2/hu unknown
- 2012-12-27 LT LT12861811T patent/LT2797927T/lt unknown
- 2012-12-27 PT PT128618113T patent/PT2797927T/pt unknown
- 2012-12-27 AU AU2012363558A patent/AU2012363558C1/en active Active
- 2012-12-27 ES ES12861811T patent/ES2751608T3/es active Active
- 2012-12-27 SG SG10201701999QA patent/SG10201701999QA/en unknown
- 2012-12-27 RU RU2017124993A patent/RU2705577C2/ru active
- 2012-12-27 JP JP2014550010A patent/JP5797345B2/ja active Active
- 2012-12-27 KR KR20120154061A patent/KR101490761B1/ko active IP Right Grant
- 2012-12-28 TW TW101151181A patent/TWI462927B/zh active
-
2014
- 2014-06-16 MX MX2019003468A patent/MX2019003468A/es unknown
- 2014-06-26 CL CL2014001729A patent/CL2014001729A1/es unknown
- 2014-06-27 PH PH12014501504A patent/PH12014501504A1/en unknown
- 2014-06-29 IL IL233441A patent/IL233441B/en active IP Right Grant
- 2014-07-25 CO CO14162082A patent/CO7010840A2/es active IP Right Grant
- 2014-07-29 ZA ZA2014/05583A patent/ZA201405583B/en unknown
-
2015
- 2015-02-11 HK HK15101503.1A patent/HK1200833A1/xx unknown
-
2019
- 2019-04-28 IL IL266285A patent/IL266285B/en unknown
- 2019-10-11 HR HRP20191840TT patent/HRP20191840T8/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014DN06101A (fr) | ||
| WO2011093684A3 (fr) | Dérivés thiéno[3,2-d]pyrimidines avec activité inhibitrice sur protéines kinases | |
| WO2011093672A3 (fr) | Dérivés hétéroaryle bicyclique ayant une activité inhibitrice de protéine kinase | |
| SA515360229B1 (ar) | مثبطات عامل التمايز والنمو 8 | |
| SG11201408052WA (en) | IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AS KINASE INHIBITORS | |
| WO2011062372A3 (fr) | Composés thiéno[3,2-d]pyrimidines substitués dans les positions 2, 4, 7, en tant qu'inhibiteurs de protéine kinases | |
| WO2011049332A3 (fr) | Composés thiéno[3,2-d]pyrimidines substitués dans les positions 2 et 7 en tant qu'inhibiteurs de protéine kinase | |
| SI2324008T1 (sl) | 3,4-diarilpirazoli kot protein-kinazni inhibitorji | |
| TW200833693A (en) | Substituted pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors | |
| UA99141C2 (ru) | Замещенные производные индазола, активные в качестве ингибиторов киназы | |
| WO2011014795A3 (fr) | Composés et compositions pouvant servir d'inhibiteurs de la kinase syk | |
| AU2009258496A8 (en) | Sulfur-containing heterocyclic derivative having beta-secretase-inhibiting activity | |
| MY186126A (en) | Quinazoline inhibitors of activating mutant forms of epidermal growth factor receptor | |
| AU2012284088A8 (en) | Heterocyclic compounds and uses thereof | |
| UA115320C2 (uk) | Інгібітори кінази | |
| JO2885B1 (en) | Protein kinase inhibitors | |
| WO2012030160A3 (fr) | Dérivés de quinoline ou de quinazoline ayant une activité induisant l'apoptose sur les cellules | |
| MX337849B (es) | Composiciones y metodos para inhibicion de la via jak. | |
| UA102219C2 (ru) | Замещенные пиразолохиназолиновые производные, способ их получения и их применения как ингибиторов киназы | |
| MX2018011592A (es) | Compuesto que tiene actividad inhibitoria de idh mutante, metodo de preparacion y usos del mismo. | |
| WO2014072930A3 (fr) | Dérivés pyridine fondus, en tant qu'agents antibactériens | |
| SG10201809506TA (en) | Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions | |
| AU2012225365A8 (en) | Peptide deformylase inhibitors | |
| WO2011090317A3 (fr) | Dérivés imidazopyrazinones avec activité induisant apoptose sur cellules | |
| WO2011140682A8 (fr) | (2e)-3-phényl-n-[2,2,2-trifluoro-1-[[(8-quinoléine-amino)thiométhyl]- amino]éthyl]-2-acrylamide et ses utilisations pharmaceutiques |